Ask AI
ProCE Banner Activity

Optimización del tratamiento del linfoma de células del manto: orientación basada en casos prácticos elaborada por expertos de la UE

PDF

Este módulo presenta las perspectivas de expertos de la UE sobre el algoritmo de tratamiento actual, las directrices y los enfoques basados en la evidencia para la integración óptima de los tratamientos disponibles en el manejo de pacientes con linfoma de células del manto (LCM), teniendo en cuenta la edad del paciente, su estado físico, la presencia de características de alto riesgo, las comorbilidades preexistentes y los medicamentos concomitantes.

Released: June 15, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca

Target Audience

This activity is intended for global hematology/oncology physician specialists and other healthcare professionals providing care for patients with mantle cell lymphoma. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Plan BTK inhibitor-based combination strategies for patients with treatment-naïve MCL, considering new indications, expert recommendations, and available efficacy and safety evidence

  • Select chemotherapy-free treatment strategies for appropriate patients with MCL

  • Manage treatment-related adverse events associated with targeted therapies alone or in combination to extend duration on treatment and improve clinical outcomes

Financial Disclosures

Primary Author

Mats Jerkeman, MD, PhD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeOne, Bristol Myers Squibb, Galapagos, Johnson & Johnson, Kite, Lilly, Sobi.